JP2014523398A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014523398A5 JP2014523398A5 JP2014501258A JP2014501258A JP2014523398A5 JP 2014523398 A5 JP2014523398 A5 JP 2014523398A5 JP 2014501258 A JP2014501258 A JP 2014501258A JP 2014501258 A JP2014501258 A JP 2014501258A JP 2014523398 A5 JP2014523398 A5 JP 2014523398A5
- Authority
- JP
- Japan
- Prior art keywords
- agent
- integrin
- beta
- antibody
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003795 chemical substances by application Substances 0.000 claims 18
- 102000012355 Integrin beta1 Human genes 0.000 claims 17
- 108010022222 Integrin beta1 Proteins 0.000 claims 17
- 239000000203 mixture Substances 0.000 claims 10
- 210000004881 tumor cell Anatomy 0.000 claims 7
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims 6
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 6
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 6
- 229920001184 polypeptide Polymers 0.000 claims 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims 5
- 230000004614 tumor growth Effects 0.000 claims 5
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 4
- 208000005017 glioblastoma Diseases 0.000 claims 4
- 239000003112 inhibitor Substances 0.000 claims 4
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 230000001404 mediated effect Effects 0.000 claims 3
- 201000010915 Glioblastoma multiforme Diseases 0.000 claims 2
- 210000001072 colon Anatomy 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 230000014509 gene expression Effects 0.000 claims 2
- 238000011577 humanized mouse model Methods 0.000 claims 2
- 102000006495 integrins Human genes 0.000 claims 2
- 108010044426 integrins Proteins 0.000 claims 2
- 210000003734 kidney Anatomy 0.000 claims 2
- 210000004185 liver Anatomy 0.000 claims 2
- 210000004072 lung Anatomy 0.000 claims 2
- 230000004565 tumor cell growth Effects 0.000 claims 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 108091027967 Small hairpin RNA Proteins 0.000 claims 1
- 230000000903 blocking effect Effects 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 238000002716 delivery method Methods 0.000 claims 1
- 210000002744 extracellular matrix Anatomy 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 238000003384 imaging method Methods 0.000 claims 1
- 210000002429 large intestine Anatomy 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 108020004999 messenger RNA Proteins 0.000 claims 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 238000002271 resection Methods 0.000 claims 1
- 239000004055 small Interfering RNA Substances 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161466791P | 2011-03-23 | 2011-03-23 | |
| US61/466,791 | 2011-03-23 | ||
| PCT/US2012/030204 WO2012129448A1 (en) | 2011-03-23 | 2012-03-22 | Methods and compositions for improving antiangiogenic therapy with anti-integrins |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014523398A JP2014523398A (ja) | 2014-09-11 |
| JP2014523398A5 true JP2014523398A5 (OSRAM) | 2015-05-07 |
Family
ID=46879749
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014501258A Pending JP2014523398A (ja) | 2011-03-23 | 2012-03-22 | 抗−インテグリンを用いた抗血管新生療法を改良するための方法及び組成物 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US20140079637A1 (OSRAM) |
| EP (1) | EP2688585B1 (OSRAM) |
| JP (1) | JP2014523398A (OSRAM) |
| KR (1) | KR20140030153A (OSRAM) |
| CN (1) | CN103561761A (OSRAM) |
| AU (1) | AU2012230809B2 (OSRAM) |
| CA (1) | CA2830908C (OSRAM) |
| ES (1) | ES2699532T3 (OSRAM) |
| WO (1) | WO2012129448A1 (OSRAM) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2688585B1 (en) * | 2011-03-23 | 2018-09-05 | The Regents of The University of California | Methods and compositions for improving antiangiogenic therapy with anti-integrins |
| US10023638B2 (en) | 2012-12-26 | 2018-07-17 | Oncosynergy, Inc. | Anti-integrin β1 antibody compositions and methods of use thereof |
| EP3067698A1 (en) | 2015-03-11 | 2016-09-14 | Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) | Pd-ecgf as biomarker of cancer |
| EP3067369A1 (en) | 2015-03-11 | 2016-09-14 | Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) | Methods and compositions for the treatment of anti-angiogenic resistant cancer |
| US11578110B2 (en) | 2015-08-25 | 2023-02-14 | Histide Ag | Compounds for inducing tissue formation and uses thereof |
| WO2017046229A1 (en) * | 2015-09-17 | 2017-03-23 | Histide Ag | Pharmaceutical association of growth factor receptor agonist and adhesion protein inhibitor for converting a neoplastic cell into a non-neoplastic cell and uses thereof |
| EP3998076A1 (en) * | 2015-09-17 | 2022-05-18 | Histide AG | Pharmaceutical association of growth factor receptor agonist and adhesion protein inhibitor for converting a neoplastic cell into a non-neoplastic cell and uses thereof |
| IL299622A (en) * | 2015-09-17 | 2023-03-01 | Histide Ag | A pharmaceutical composition containing a growth receptor agonist and an adhesion protein inhibitor for converting a neoplastic cell into a non-neoplastic cell and its uses |
| WO2020145669A1 (ko) * | 2019-01-10 | 2020-07-16 | 에스지메디칼 주식회사 | 항 베타 1 인테그린 인간화 항체 및 이를 포함하는 암치료용 약학 조성물 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5272263A (en) * | 1989-04-28 | 1993-12-21 | Biogen, Inc. | DNA sequences encoding vascular cell adhesion molecules (VCAMS) |
| US6033665A (en) | 1989-09-27 | 2000-03-07 | Elan Pharmaceuticals, Inc. | Compositions and methods for modulating leukocyte adhesion to brain endothelial cells |
| US6165467A (en) | 1991-07-20 | 2000-12-26 | Yoshihide Hagiwara | Stabilized human monoclonal antibody preparation |
| US5840300A (en) | 1995-09-11 | 1998-11-24 | Trustees Of The University Of Pennsylvania | Methods and compositions comprising single chain recombinant antibodies |
| US5846536A (en) * | 1996-10-04 | 1998-12-08 | The Regents Of The University Of California | Restoration of normal phenotype in cancer cells |
| US6596276B1 (en) | 1997-09-30 | 2003-07-22 | Beth Israel Deaconess Medical Center | Method for inhibiting tumor angiogenesis in a living subject |
| DK1075277T4 (da) * | 1998-05-08 | 2012-12-17 | Univ California | Fremgangsmåder til detektion og inhibering af angiogenese |
| ATE538794T1 (de) | 1999-01-13 | 2012-01-15 | Bayer Healthcare Llc | Gamma carboxyarylsubstituierte diphenylharnstoffverbindungen als p38 kinasehemmer |
| US7928239B2 (en) | 1999-01-13 | 2011-04-19 | Bayer Healthcare Llc | Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas |
| EP1140840B1 (en) | 1999-01-13 | 2006-03-22 | Bayer Pharmaceuticals Corp. | -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| US6949245B1 (en) | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
| US6716410B1 (en) | 1999-10-26 | 2004-04-06 | The Regents Of The University Of California | Reagents and methods for diagnosing, imaging and treating atherosclerotic disease |
| JP3789066B2 (ja) | 1999-12-08 | 2006-06-21 | 三菱電機株式会社 | 液晶表示装置 |
| US8725620B2 (en) | 2000-07-10 | 2014-05-13 | Nobuyoshi Morimoto | System and method for negotiating improved terms for products and services being purchased through the internet |
| US6878714B2 (en) | 2001-01-12 | 2005-04-12 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
| US6995162B2 (en) | 2001-01-12 | 2006-02-07 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
| EP1401477A4 (en) * | 2001-05-25 | 2005-02-02 | Human Genome Sciences | CHIMIOKINE BETA-1 HYBRID PROTEINS |
| EP1414491A4 (en) | 2001-07-09 | 2005-07-06 | Elan Pharm Inc | METHOD OF INHIBITING THE TOXICITY OF AMYLOID |
| AU2002365899B2 (en) | 2001-12-04 | 2007-09-13 | Onyx Pharmaceuticals, Inc. | RAF-MEK-ERK pathway inhibitors to treat cancer |
| US8637553B2 (en) | 2003-07-23 | 2014-01-28 | Bayer Healthcare Llc | Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions |
| WO2005070891A2 (en) | 2004-01-23 | 2005-08-04 | Amgen Inc | Compounds and methods of use |
| US7618627B2 (en) * | 2004-06-03 | 2009-11-17 | The Regents Of The University Of California | Method of increasing radiation sensitivity by inhibition of beta one integrin |
| JP2008546805A (ja) | 2005-06-23 | 2008-12-25 | メディミューン，エルエルシー | 最適な凝集および断片化プロフィールを有する抗体製剤 |
| AR059066A1 (es) | 2006-01-27 | 2008-03-12 | Amgen Inc | Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf) |
| JP4997432B2 (ja) | 2006-02-10 | 2012-08-08 | 学校法人慶應義塾 | 神経幹細胞の増殖抑制剤 |
| KR101454491B1 (ko) * | 2006-03-21 | 2014-10-29 | 제넨테크, 인크. | 알파5베타1 길항제를 포함하는 조합 치료법 |
| ZA200807754B (en) * | 2006-03-21 | 2009-12-30 | Genentech Inc | Combinatorial therapy involving alpha5beta1 antagonists |
| WO2008031064A1 (en) * | 2006-09-07 | 2008-03-13 | University Of South Florida | Hyd1 peptides as anti-cancer agents |
| WO2009009114A2 (en) * | 2007-07-12 | 2009-01-15 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for treating and diagnosing cancer |
| JP2010534685A (ja) * | 2007-07-27 | 2010-11-11 | ファセット バイオテック コーポレイション | チロシンキナーゼ阻害剤およびインテグリンα５β１（ＣＤ４９Ｅ）に対する抗体を含む薬学的な組み合わせ |
| EP2060287B1 (de) * | 2007-11-14 | 2011-06-15 | BrainLAB AG | Medikamentenzuführungssystem für CED (Convection Enhanced Delivery)-Katheterinfusionen |
| CA2734863A1 (en) * | 2008-08-20 | 2010-02-25 | New York Blood Center, Inc. | Regulation of integrin surface expression |
| EP2379596A1 (en) * | 2008-12-23 | 2011-10-26 | AstraZeneca AB | Targeted binding agents directed to 5 1 and uses therefor |
| RU2011142974A (ru) * | 2009-03-25 | 2013-04-27 | Дженентек, Инк. | НОВЫЕ АНТИТЕЛА ПРОТИВ α5β1 И ИХ ПРИМЕНЕНИЕ |
| EP2688585B1 (en) * | 2011-03-23 | 2018-09-05 | The Regents of The University of California | Methods and compositions for improving antiangiogenic therapy with anti-integrins |
| US10023638B2 (en) * | 2012-12-26 | 2018-07-17 | Oncosynergy, Inc. | Anti-integrin β1 antibody compositions and methods of use thereof |
-
2012
- 2012-03-22 EP EP12760157.3A patent/EP2688585B1/en active Active
- 2012-03-22 AU AU2012230809A patent/AU2012230809B2/en active Active
- 2012-03-22 CA CA2830908A patent/CA2830908C/en active Active
- 2012-03-22 WO PCT/US2012/030204 patent/WO2012129448A1/en not_active Ceased
- 2012-03-22 CN CN201280024596.8A patent/CN103561761A/zh active Pending
- 2012-03-22 ES ES12760157T patent/ES2699532T3/es active Active
- 2012-03-22 KR KR1020137027236A patent/KR20140030153A/ko not_active Ceased
- 2012-03-22 US US14/006,669 patent/US20140079637A1/en not_active Abandoned
- 2012-03-22 JP JP2014501258A patent/JP2014523398A/ja active Pending
-
2018
- 2018-01-12 US US15/869,970 patent/US11185585B2/en active Active
-
2021
- 2021-10-27 US US17/512,500 patent/US20220111045A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014523398A5 (OSRAM) | ||
| Ohri et al. | Radiotherapy for hepatocellular carcinoma: new indications and directions for future study | |
| Gingis-Velitski et al. | Host response to short-term, single-agent chemotherapy induces matrix metalloproteinase-9 expression and accelerates metastasis in mice | |
| Adamali et al. | Current and novel drug therapies for idiopathic pulmonary fibrosis | |
| Ning et al. | Therapeutic strategies targeting cancer stem cells | |
| Cho et al. | Therapeutic potential of metformin in papillary thyroid cancer in vitro and in vivo | |
| US12350302B2 (en) | Dosing regime and formulations for type B adenoviruses | |
| JP2012067116A5 (OSRAM) | ||
| Liu et al. | 177Lu-labeled antibodies for EGFR-targeted SPECT/CT imaging and radioimmunotherapy in a preclinical head and neck carcinoma model | |
| RU2016129287A (ru) | Лечение злокачественных опухолей с применением комбинаций ингибиторов erk и raf | |
| RU2016109811A (ru) | Лечение рака комбинацией антагониста pd-1 и динациклиба | |
| JP2016530323A5 (OSRAM) | ||
| JP2008507536A5 (OSRAM) | ||
| ME02470B (me) | Nanočesтice nabijene sa hemoterapeutskim anтitumorskim lekom | |
| JP2017506662A5 (OSRAM) | ||
| Cho et al. | Phase Ib/II study of the pan-cyclin-dependent kinase inhibitor roniciclib in combination with chemotherapy in patients with extensive-disease small-cell lung cancer | |
| JP2014511383A5 (OSRAM) | ||
| JP2019532047A5 (OSRAM) | ||
| Mayer et al. | SABRE-B: an evaluation of paclitaxel and bevacizumab with or without sunitinib as first-line treatment of metastatic breast cancer | |
| CN104623663B (zh) | 评估癌症于治疗后情况的方法及其相关应用 | |
| Zhang et al. | Management of castrate resistant prostate cancer—recent advances and optimal sequence of treatments | |
| Selvaggi et al. | Wingless/It/β-catenin signaling in liver metastasis from colorectal cancer: A focus on biological mechanisms and therapeutic opportunities | |
| BR112013021860A2 (pt) | anticorpo anti-tnfalpha humanizado | |
| Hoag et al. | Association of cetuximab with adverse pulmonary events in cancer patients: a comprehensive review | |
| Chen et al. | Enhanced Theranostic Efficacy of 89Zr and 177Lu-Labeled Aflibercept in Renal Cancer: A Viable Option for Clinical Practice |